From Wikipedia, the free encyclopedia - View original article
Evidence-based medicine (EBM) is defined as "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients." Trisha Greenhalgh and Anna Donald define it more specifically as "the use of mathematical estimates of the risk of benefit and harm, derived from high-quality research on population samples, to inform clinical decision-making in the diagnosis, investigation or management of individual patients." To broaden its application from individual patients to health care services in general and to allied health professions, it is also known as Evidence Informed Healthcare or Evidence Based Health Care or Evidence-Based Practice.
In practice, clinicians contextualize the best available research evidence by integrating it with their individual clinical expertise and their patient's values and expectations. The incorporation of patient values and clinical expertise in EBM partly recognizes the fact that many aspects of health care depend on individual factors. These include variations in individual physiology and pathology, and quality-of-life and value-of-life judgments. These factors are only partially subjected to scientific inquiry and sometimes even cannot be assessed in controlled experimental settings. Application of available evidence is therefore dependent on patient circumstances and preferences, and remains subject to input from personal, political, philosophical, religious, ethical, economic, and aesthetic values. This has led to a shift from the original term Evidence 'Based' Medicine to Evidence 'Informed' Healthcare, to emphasize that decisions need not necessarily be based or complying with the evidence.
The broad field of Evidence Based Medicine would include rigorous and systematic analysis of published literature to synthesize high quality evidence, such as systematic reviews. It could also be referring to a medical ‘movement’, where advocates work to popularize the method and usefulness of the practice of EBM in the public, patient communities, educational institutions, and continuing education of practicing professionals.
Evidence-based medicine (EBM) has evolved from the critical need to bridge the gap between research and practice. EBM applies research information (evidence) to clinical practice, emphasizing the importance of the use of quantitative (as well as qualitative) evidence in the "art" of clinical decision making. It aims to make decision making more structured and objective by better reflecting the evidence from research. By introducing the use of research information in clinical decision making, particularly from clinical epidemiology, EBM has driven a transformation of clinical practice and medical education.
In 1996 David Sackett wrote that "evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients." This definition, put forward by one of the original proponents of evidence-based medicine, has since been adopted by major organizations, including the Cochrane Collaboration and the Centre for Evidence Based Medicine.
An evidence-based health service tends to generate an increase in the competence of health service decision makers and is the practice of evidence-based medicine at the organizational or institutional level. It strengthens the motivation of any health service decision-maker to use scientific methods when making a decision.More details of this approach to health services and public health have been discussed in a book titled evidence-based healthcare & public health. Research by Michael Fischer and colleagues at the University of Oxford finds that evidence-based rules may not readily 'hybridise' with experience-based practices orientated towards ethical clinical judgement, and can lead to contradictions, contest, and unintended crises. In their recent, large study of the UK health knowledge economy, they find the most effective 'knowledge leaders' (managers and clinical leaders) use a broad range of management knowledge in their decision making, rather than just formal evidence. Evidence-based guidelines may provide the basis for 'governmentality' in health care and consequently play a central role in the distant governance of contemporary health care systems.
The results of population-based research form the foundation of evidence-based medicine. It aims to use the experience of a population of patients reported in the research literature to guide decision making in practice. This practice of evidence-based medicine requires the application of population-based data to the care of an individual patient. In the past, we have relied on the experience of physicians or other health care workers to make decisions about therapy. In the current information era, this approach would be suboptimal as health care workers rapidly find themselves unable to cope with the influx of a huge variety of new information, from the irrelevant to the very important. Therefore, evidence-based decision making gradually emerged as a solution to integrate the best research evidence with clinical expertise and patient values and expectations as practiced by the individual health care provider. The concepts and ideas attributed to and labeled collectively as EBM/EBHC have now become a part of daily clinical lives, and health care professionals increasingly hear about evidence-based guidelines, care paths, questions and solutions. The controversy has shifted from whether to implement the new concepts to how to do so sensibly and efficiently, while avoiding potential problems associated with a number of misconceptions about what EBM/EBHC is and what it is not. The EBM/EBHC-related concepts of hierarchy of evidence, meta-analyses, confidence intervals, study design, and so forth are so widespread, that health care professionals have no choice but to become familiar with EBM/EBHC principles and methodologies.
The five steps of EBM in practice were first described in 1992 and the experience of delegates attending the 2003 Conference of Evidence-Based Health Care Teachers and Developers was summarized into five steps and published in 2005. This five step process can broadly be categorized as:
Using techniques from science, engineering and statistics, such as the systematic review of medical literature, meta-analysis, risk-benefit analysis, and randomized controlled trials (RCTs), EBM aims for the ideal that healthcare professionals should make "conscientious, explicit, and judicious use of current best evidence" in their everyday practice. Ex cathedra statements by the "medical expert" are considered to be the least valid form of evidence. All "experts" are now expected to reference their pronouncements to scientific studies.
The systematic review of published research studies is a major method used for evaluating particular treatments. The Cochrane Collaboration is one of the best-known, respected examples of systematic reviews. Like other collections of systematic reviews, it requires authors to provide a detailed and repeatable plan of their literature search and evaluations of the evidence. Once all the best evidence is assessed, treatment is categorized as (1) likely to be beneficial, (2) likely to be harmful, or (3) evidence did not support either benefit or harm.
A 2007 analysis of 1016 systematic reviews from all 50 Cochrane Collaboration Review Groups found that 44% of the reviews concluded that the intervention was likely to be beneficial, 7% concluded that the intervention was likely to be harmful, and 49% concluded that evidence did not support either benefit or harm. 96% recommended further research. A 2001 review of 160 Cochrane systematic reviews (excluding complementary treatments) in the 1998 database revealed that, according to two readers, 41.3% concluded positive or possibly positive effect, 20% concluded evidence of no effect, 8.1% concluded net harmful effects, and 21.3% of the reviews concluded insufficient evidence. A review of 145 alternative medicine Cochrane reviews using the 2004 database revealed that 38.4% concluded positive effect or possibly positive (12.4%) effect, 4.8% concluded no effect, 0.69% concluded harmful effect, and 56.6% concluded insufficient evidence.
Evidence quality can be assessed based on the source type (from meta-analyses and systematic reviews of triple-blind randomized clinical trials with concealment of allocation and no attrition at the top end, down to conventional wisdom at the bottom), as well as other factors including statistical validity, clinical relevance, currency, and peer-review acceptance. Evidence-based medicine categorizes different types of clinical evidence and rates or grades them according to the strength of their freedom from the various biases that beset medical research. For example, the strongest evidence for therapeutic interventions is provided by systematic review of randomized, triple-blind, placebo-controlled trials with allocation concealment and complete follow-up involving a homogeneous patient population and medical condition. In contrast, patient testimonials, case reports, and even expert opinion (however some critics have argued that expert opinion "does not belong in the rankings of the quality of empirical evidence because it does not represent a form of empirical evidence" and continue that "expert opinion would seem to be a separate, complex type of knowledge that would not fit into hierarchies otherwise limited to empirical evidence alone.") have little value as proof because of the placebo effect, the biases inherent in observation and reporting of cases, difficulties in ascertaining who is an expert and more.
Systems to stratify evidence by quality have been developed, such as this one by the United States Preventive Services Task Force for ranking evidence about the effectiveness of treatments or screening:
Most of the evidence ranking schemes grade evidence for therapy and prevention, but not for diagnostic tests, prognostic markers, or harm. The Oxford CEBM Levels of Evidence addresses this issue and provides 'Levels' of evidence for claims about prognosis, diagnosis, treatment benefits, treatment harms, and screening. The original CEBM Levels was first released in September 2000 for Evidence-Based On Call to make the process of finding evidence feasible and its results explicit. In 2011 the Oxford CEBM Levels were redesigned by international team including Jeremy Howick, Sir Iain Chalmers, Paul Glasziou (chair), Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, and Hazel Thornton (and help from Olive Goddard and Mary Hodgkinson) re-designed the Oxford CEBM Levels to make it more understandable and to take into account recent developments in evidence ranking schemes. The Oxford CEBM Levels of Evidence have been used by patients, clinicians and also to develop clinical guidelines including recommendations for the optimal use of phototherapy and topical therapy in psoriasis and guidelines for the use of the BCLC staging system for diagnosing and monitoring hepatocellular carcinoma in Canada.
In guidelines and other publications, recommendation for a clinical service is classified by the balance of risk versus benefit of the service and the level of evidence on which this information is based. The U.S. Preventive Services Task Force uses:
A system was developed by the GRADE working group and takes into account more dimensions than just the quality of medical research. It requires users of GRADE (short for Grading of Recommendations Assessment, Development and Evaluation) who are performing an assessment of the quality of evidence, usually as part of a systematic review, to consider the impact of different factors on their confidence in the results. Authors of GRADE tables, grade the quality of evidence into four levels, on the basis of their confidence in the observed effect(a numerical value) being close to what the true effect is. The confidence value is based on judgements assigned in five different domains in a structured manner. The GRADE working group defines 'quality of evidence' and 'strength of recommendations' based on the quality as two different concepts which are commonly confused with each other.
Systematic reviews may include Randomized Controlled trials that have low risk of bias, or, observational studies that have high risk of bias. In the case of Randomized controlled trials, the quality of evidence is high, but can be downgraded in five different domains.
In the case of observational studies, the quality of evidence starts of lower and may be upgraded in three domains in addition to being subject to downgrading.
Meaning of the levels of Quality of evidence as per GRADE
Guideline panelists may make Strong or Weak recommendations on the basis of further criteria. Some of the important criteria are:
Despite the differences between systems, the purposes are the same: to guide users of clinical research information on which studies are likely to be most valid. However, the individual studies still require careful critical appraisal.
Evidence-based medicine attempts to express clinical benefits of tests and treatments using mathematical methods. Tools used by practitioners of evidence-based medicine include:
The pre-test odds of a particular diagnosis, multiplied by the likelihood ratio, determines the post-test odds. (Odds can be calculated from, and then converted to, the [more familiar] probability.) This reflects Bayes' theorem. The differences in likelihood ratio between clinical tests can be used to prioritize clinical tests according to their usefulness in a given clinical situation.
The area under the receiver operating characteristic curve (AUC-ROC) reflects the relationship between sensitivity and specificity for a given test. High-quality tests will have an AUC-ROC approaching 1, and high-quality publications about clinical tests will provide information about the AUC-ROC. Cutoff values for positive and negative tests can influence specificity and sensitivity, but they do not affect AUC-ROC.
Number needed to treat or Number needed to harm are ways of expressing the effectiveness and safety of an intervention in a way that is clinically meaningful. In general, NNT is always computed with respect to two treatments A and B, with A typically a drug and B a placebo (in our example above, A is a 5-year treatment with the hypothetical drug, and B is no treatment). A defined endpoint has to be specified (in our example: the appearance of colon cancer in the 5 year period). If the probabilities pA and pB of this endpoint under treatments A and B, respectively, are known, then the NNT is computed as 1/(pB-pA). If it is said that the NNT for breast mammography is 285 this means that 285 mammograms need to be performed to diagnose one case of breast cancer. As another example, an NNT of 4 means if 4 patients are treated, only one would respond.
An NNT of 1 is the most effective and means each patient treated responds, e.g., in comparing antibiotics with placebo in the eradication of Helicobacter pylori. An NNT of 2 or 3 indicates that a treatment is quite effective (with one patient in 2 or 3 responding to the treatment). An NNT of 20 to 40 can still be considered clinically effective.
Evidence-based medicine attempts to objectively evaluate the quality of clinical research by critically assessing techniques reported by researchers in their publications.
Although evidence-based medicine is regarded as the gold standard of conventional clinical practice, there are a number of limitations and criticisms of its use, many of which remain unresolved despite nearly two centuries of debate.
Standard descriptions about mental illnesses, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), have been criticized as incompletely justified by scientific evidence. In many cases, it is unknown whether a particular "disease" has one, several, or no underlying biological causes, with controversy arising over whether some diseases are merely an artifact of the attempt to construct a unified classification scheme, rather than a "real" disease.
While some experts point to statistics in support of the idea that a lack of adoption of research findings results in suboptimal treatment for many patients, others emphasize the importance of the skill of the practitioner and the customization of the treatment to fit individual needs. There is some controversy over whether mental illnesses are too complex for broad population studies to be helpful.
Traces of evidence-based medicine's origin can be found in ancient Greece. Although testing medical interventions for efficacy has existed since the time of Avicenna's The Canon of Medicine in the 11th century, it was only in the 20th century that this effort evolved to impact almost all fields of health care and policy.
In 1967, the American physician and mathematician Alvan R. Feinstein published his groundbreaking work Clinical Judgment, which together with Archie Cochrane’s famous book Effectiveness and Efficiency (1972) led to an increasing acceptance of clinical epidemiology and controlled studies during the 1970s and 1980s and paved the way for the institutional development of EBM in the 1990s. Cochrane's efforts were recognized by the fact that an international network for efficacy assessment in medicine – the Cochrane Collaboration – was posthumously named after him. However, Cochrane himself did not live to see the foundation and institutionalization of the EBM movement and Feinstein became later in his life one of its sharpest methodological critics.
The explicit methodologies used to determine "best evidence" were largely established by the McMaster University research group led by David Sackett and Gordon Guyatt. Guyatt later coined the term "evidence-based" in 1990. The term "evidence-based medicine" first appeared in the medical literature in 1992 in a paper by Guyatt et al. Relevant journals include the British Medical Journal's Clinical Evidence, the Journal of Evidence-Based Healthcare and Evidence Based Health Policy. All of these were co-founded by Anna Donald, an Australian pioneer in the discipline.
Advances in genetics have enabled a more detailed understanding of the impact of genetics in disease. Large collaborative research projects (for example, the Human genome project) have laid the groundwork for the understanding of the roles of genes in normal human development and physiology, revealed single nucleotide polymorphisms (SNPs) that account for some of the genetic variability between individuals, and made possible the use of genome-wide association studies (GWAS) to examine genetic variation and risk for many common diseases.
Beyond germline genetics, molecular pathology is a much wider open area for therapeutic and preventive applications based on EBM. Inter-personal difference of molecular pathology is diverse, so as inter-personal difference in the exposome, which influence disease processes through the interactome within the tissue microenvironment, differentially from person to person. Thus, in current and future EBM, evidence needs to be more and more individualized towards precision medicine (or personalized medicine). As the theoretical basis of precision medicine, the "unique disease principle" (which was first described in neoplastic diseases as the unique tumor principle) emerged to embrace the ubiquitous phenomenon of heterogeneity of disease etiology and pathogenesis. As the exposome is a common concept of epidemiology, precision medicine is intertwined with molecular pathological epidemiology (MPE). MPE research contributes to EBM, by means of giving evidence for potential clinical biomarkers in precision medicine.
Insurance companies in the United States and public insurers in other countries usually wait for drug use approval based on evidence-based guidelines before funding a treatment. Where approval for a drug has been given, and subsequent evidence-based findings indicating that a drug may be less safe than originally anticipated, some insurers in the U.S. have reacted very cautiously and withdrawn funding. For example, an older generic statin drug had been shown to reduce mortality, but a newer and much more expensive statin drug was found to lower cholesterol more effectively. However, evidence came to light about safety concerns with the new drug which caused some insurers to stop funding it even though marketing approval was not withdrawn.
Some people are willing to take their chances to gamble their health on the success of new drugs or old drugs in new situations which may not yet have been fully tested in clinical trials. However insurance companies are reluctant to take on the job of funding such treatments, preferring instead to take the safer route of awaiting the results of clinical testing and leaving the funding of such trials to the manufacturer seeking a license.
Sometimes caution errs in the other direction. Kaiser Permanente did not change its methods of evaluating whether or not new therapies were too "experimental" to be covered until it was successfully sued twice: once for delaying in vitro fertilization treatments for two years after the courts determined that scientific evidence of efficacy and safety had reached the "reasonable" stage; and in another case where Kaiser refused to pay for liver transplantation in infants when it had already been shown to be effective in adults, on the basis that use in infants was still "experimental." Here again, the problem of induction plays a key role in arguments.
There has been discussion of applying what has been learned from evidence-based medicine to public policy. In his 1996 inaugural speech as President of the Royal Statistical Society, Adrian Smith held out evidence-based medicine as an exemplar for all public policy. He proposed that "evidence-based policy" should be established for education, prisons and policing policy and all areas of government work.
|Look up evidence-based medicine in Wiktionary, the free dictionary.|